LUX Infusion (the "Company"), a clinician-led infusion service network, today announced the availability of Qfitlia ...

A new class of medicines offers steadier protection with fewer injections, while gene therapy is beginning to test the promise of a one-time treatment.

NEWARK, Del, June 25, 2024 (GLOBE NEWSWIRE) -- The hemophilia treatment market is forecast to reach USD 12.1 billion in 2024. Between 2024 and 2034, hemophilia treatment is predicted to register a ...

A global study involving McMaster University researchers has trialed a potential new treatment that could be a game-changer for people living with hemophilia A, a life-threatening genetic blood ...

Steven W. Pipe, MD, explores the potential advantages and challenges of fitusiran, a promising small interfering RNA therapy for hemophilia A, discussing its subcutaneous nature, low administration ...

"With hemophilia management being complex, our guideline provides clarity, guiding treatment decisions with evidence-based insight, yet highlighting the importance of making treatment decisions ...

Russell P. Gollard, MD, FACP, discusses coverage decisions for expensive treatments in hemophilia, including total cost of care, drug availability, and real-world evidence. Russell P. Gollard, MD, ...

Chicago, March 24, 2025 (GLOBE NEWSWIRE) -- As per the newest research from Astute Analytica, the Japan hemophilia treatment market was valued at US$ 556.69 million in 2024 and is expected to reach ...

Hemophilia A is a bleeding disorder caused by a deficiency in factor VIII. Treatment options for hemophilia A include ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Pfizer has abandoned development of a ...

The FDA has approved the first hemophilia B gene therapy, a one-time treatment that addresses a root cause of this inherited disorder and potentially eliminates the need for regular infusions that ...